The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women

Menopause

Volumn 18, Issue 1, 2011, Pages 6-7

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BAZEDOXIFENE; CENTCHROMAN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ICI 182876; IDOXIFENE; LASOFOXIFENE; OSPEMIFENE; PLACEBO; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CLINICAL TRIAL (TOPIC); DRUG INDUCED CANCER; EDITORIAL; ENDOMETRIAL DISEASE; ENDOMETRIUM POLYP; FEMALE; FEMALE GENITAL SYSTEM; FRAGILITY FRACTURE; HORMONE RECEPTOR INTERACTION; HUMAN; MORBIDITY; MORTALITY; OSTEOPOROSIS; OVARY CYST; POSTMENOPAUSE; UTERUS CANCER;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES;

EID: 78651397151     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318203a46b     Document Type: Editorial

References (22)

1. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005;5:343-357.
2. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging 2010;27:533-544.
3. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science (New York, NY) 2002;296:1642-1644.
4. McDonnell DP. Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen. J Soc Gynecol Investig 2000;7:S10-S15.
5. McDonnell DP, Chang CY, Norris JD. Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann N Y Acad Sci 2001;949:16-35.
6. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-2588.
7. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-696.
8. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386.
9. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052.
10. Palacios S. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Curr Med Res Opin 2010;26:1553-1563.
11. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 2008;26:5227-5232.
12. Delmas PD, Calvo G, Boers M, et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 2002;13:1-5.
13. Stein CM, Ray WA. The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med 2010;363:1367-1370; discussion e21.
14. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
15. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-1115.
16. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102-1108.
17. Ettinger B, Bainton L, Upmalis DH, Citron JT, VanGessel A. Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1997;176:112-117.
18. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
19. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-486.
20. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
21. Davies GC, Huster WJ, Shen W, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999;6: 188-195.
22. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-344.